Graphical representation of clinical outcomes for patients with myelodysplastic syndromes

References

• Tufte E. The Visual display of quantitative information. Cheshire, CT: Graphics Press; 1983.
   Google Scholar
• Fedeli U, Schievano E, Saugo M, et al. Mortality from myelodysplastic syndromes: a multiple causes of death approach. Am J Hematol 2014;89:450–451.
   PubMed Web of Science ®Google Scholar
• Polednak AP. Surveillance of US deaths related to myelodysplastic syndromes, and the need for linkages with central cancer registries. J Registry Manag 2011;38:183–189.
   PubMedGoogle Scholar
• Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 2010;116:2174–2179.
   PubMed Web of Science ®Google Scholar
• Polednak AP, Phillips C. Leukemia as a cause of death among patients with myelodysplastic syndromes (MDS) in a population- based cancer registry: improving estimates of MDS-related mortality in the population. J Registry Manag 2012;39:115–120.
   PubMedGoogle Scholar
• Rizzieri DA, O’Brien JA, Broadwater G, et al. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 2009;115:2922–2929.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Gattermann N. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes? Best Pract Res Clin Haematol 2013;26: 431–444.
   PubMed Web of Science ®Google Scholar
• Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009;33:1594–1598.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29:2240–2246.
   PubMed Web of Science ®Google Scholar
• Polednak AP. Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. Cancer Epidemiol 2013;37:569–574.
   PubMed Web of Science ®Google Scholar
• Pomeroy C, Oken MM, Rydell RE, et al. Infection in the myelodysplastic syndromes. Am J Med. 1991;90:338–344.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Sullivan LR, Sekeres MA, Shrestha NK, et al. Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis 2013;15:652–657. doi: 10.1111/tid.12130. Epub 2013 Sep 9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109: 1705–1714.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594–7603.
   PubMed Web of Science ®Google Scholar
• Bowen DT, Hellstrom-Lindberg E, Steensma DP. Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol 2014;164:610–611.
   PubMed Web of Science ®Google Scholar
• Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009;114:5251–5255.
   PubMed Web of Science ®Google Scholar
• Gattermann N. Pathophysiological and clinical aspects of iron chelation therapy in MDS. Curr Pharm Des 2012;18:3222–3234.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, de Lima M. Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. J Natl Compr Canc Netw 2013;11:1227–1233.
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013. Available from: http://www.cibmtr.org. Access verified 3 July 2015.
   Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52.
   PubMed Web of Science ®Google Scholar
• Ma X. Epidemiology of myelodysplastic syndromes. Am J Med 2012;125(Suppl. 7):S2–5.
   PubMedGoogle Scholar
• Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011;117: 7121–7125.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Iannacone MR, Yu D, et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res 2014;38:71–75.
   PubMed Web of Science ®Google Scholar
• Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood 2014;124:2793–2803.
   PubMed Web of Science ®Google Scholar
• Marcondes M, Deeg HJ. Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom? Best Pract Res Clin Haematol 2008;21:67–77.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011;306:1874–1883.
   PubMed Web of Science ®Google Scholar
• Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013;31: 2662–2670.
   PubMed Web of Science ®Google Scholar
• Pidala J, Craig BM, Lee SJ, et al. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2013;48:63–67.
   PubMed Web of Science ®Google Scholar
• Kollman C, Weis T, Switzer GE, et al. Non-HLA barriers to unrelated donor stem cell transplantation. Bone Marrow Transplant 2001;27:581–587.
   PubMed Web of Science ®Google Scholar
• Marquez Malaver FJ, Espigado Tocino I, Balsalobre Lopez P, et al. Evaluation of the pretransplantation phase of the hemopoietic stem cell program in a tertiary hospital. Transplant Proc 2008;40: 3099–3101.
   PubMed Web of Science ®Google Scholar
• Fuchs E, O’Donnell PV, Brunstein CG. Alternative transplant donor sources: is there any consensus? Curr Opin Oncol 2013;25: 173–179.
   PubMed Web of Science ®Google Scholar